Warning Letter — Estar Technologies Ltd
The FDA issued a Warning Letter to Estar Technologies Ltd. following an evaluation by the Center for Biologics Evaluation and Research (CBER).
This affects Estar Technologies Ltd. and may impact personnel involved in regulatory compliance, quality management, and biological product manufacturing.
The issuance of a Warning Letter by CBER indicates that the firm's previous responses to inspectional observations were likely insufficient to address identified regulatory non-compliance. This level of enforcement action typically suggests significant concerns regarding quality systems or product safety protocols that could lead to further administrative or legal action if not remediated.
Quality and Regulatory departments should conduct a gap analysis of their current compliance posture against CBER-specific expectations. Teams should ensure that all responses to previous inspectional observations (Form 483) are robust, documented, and fully addressed to prevent escalation to a Warning Letter.
FDA Warning Letter issued to: Estar Technologies Ltd. 04/22/2026 — Center for Biologics Evaluation and Research. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/estar-technologies-ltd-716831-04222026
Open in openFDA / FDA.gov